Rosemont Delivers On US Expansion Plans By Snapping Up Sabal

Second Acquisition In A Month Gives UK Liquids Specialist A Bridgehead In The US

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

UK liquids specialist Rosemont Pharmaceuticals has delivered on promises to expand into the US market by striking a deal to acquire Georgia-based distributor Sabal Therapeutics.

UK and USA jigsaw puzzle pieces joined together
UK-based Rosemont has made an acquisition in the US • Source: Shutterstock

Rosemont Pharmaceuticals is making major inroads into the US market after the UK-based liquids specialist struck a deal to acquire Sabal Therapeutics and its affiliates Metacel Pharmaceuticals, Palmetto Pharmaceuticals, Athena Bioscience and Sarras Health. The privately-owned group are distributors of prescription liquid medicines as well as tablets, based in Watkinsville, Georgia.

The deal – which Rosemont said “enhances its ability to develop products for global market” – follows indications from CEO...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By Saba Afreen

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.